Tuxobertinib
Tuxobertinib (BDTX-189) is a highly selective, allosteric inhibitor targeting oncogenic mutations in EGFR and HER2, demonstrating potent anticancer activity. It has shown efficacy in preclinical in vitro and in vivo models for non-small cell lung cancer and other solid tumors driven by these mutations.
Product Specifications
CAS Number
2414572-47-5
Product Name Alternative
Ba/F3, BLK, BDTX 189, BDTX189, BDTX-189, allosteric, mice, oral, oncogene athymic, nude, inhibit, mutants, HER1, HER2, Inhibitor, insertion, EGFR, Epidermal growth factor receptor, ErbB-1, RIP kinase, RIPK2, RIPkinase, Tuxobertinib
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
98.86% (May vary between batches)
Solubility
DMSO:41.67 mg/mL (74.27 mM)
Smiles
Clc1cc (Nc2ncnc3cc (OCCN4CCOCC4) c (NC (=O) C=C) cc23) ccc1OCc1ccccn1
Molecular Formula
C29H29ClN6O4
Molecular Weight
561.03
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
